Why the study?
In what clinical scenarios does the anti-Xa assay provide biased results for heparin monitoring?
In what clinical scenarios does the anti-Xa assay provide biased results for heparin monitoring?
The anti-Xa assay can underestimate heparin concentration in several common clinical scenarios, including AT deficiency, pregnancy, ESRD, postthrombolysis, and hyperbilirubinemia, potentially affecting patient outcomes.
Clinicians should interpret anti-Xa levels cautiously amid common biases; leaves open need for assay standardization in heparin management.
Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review. Guidelines and current literature search: we used PubMed, Medline, Embase, and MEDION, from 2000 to October 2013. Results. Anti-Xa test is widely used; however the assay underestimates heparin concentration in the presence of significant AT deficiency, pregnancy, end stage renal disease, and postthrombolysis and in patients with hyperbilirubinemia; limited published data evaluating the safety and effectiveness of anti-Xa assays for managing UH therapy is available. Conclusions and Relevance. To our knowledge this is the first paper that summarizes the most common causes in which this assay can be affected, several "day to day" clinical scenarios can modify the outcomes, and we concur that these rarely recognized scenarios can be affected by negative outcomes in the daily practice.
No takes yet. Share an insight, caveat, or question.
Vera-Aguilera et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: